


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A compound of Formula I:



I

in which:

X^1 is $-NHC(R^1)(R^2)X^3$ or $-NHX^4$;

X^2 is morpholin-4-ylcarbonyloxy hydrogen, fluoro, $-OH$, $-OR^4$, $-NHR^{15}$ or $-NR^{17}R^{18}$; and
 X^7 is hydrogen or X^2 and X^7 both represent fluoro;

X^3 is benzooxazol-2-ylcarbonyl eyano, $-C(R^7)(R^8)R^{16}$, $-C(R^6)(OR^6)_2-CH_2C(O)R^{16}$,
 $-CH=CHS(O)_2R^5$, $-C(O)CF_2C(O)NR^5R^5$, $-C(O)C(O)NR^5R^6$, $-C(O)C(O)OR^5$,
 $-C(O)CH_2OR^5$, $-C(O)CH_2N(R^6)SO_2R^5$ or $-C(O)C(O)R^5$; wherein R^5 is hydrogen,
(C_{1-4})alkyl, (C_{3-10})cycloalkyl(C_{0-6})alkyl, hetero(C_{3-10})cycloalkyl(C_{0-3})alkyl,
(C_{6-10})aryl(C_{0-6})alkyl, hetero(C_{5-10})aryl(C_{0-6})alkyl, (C_{9-10})bicycloaryl(C_{0-6})alkyl or
hetero(C_{8-10})bicycloaryl(C_{0-6})alkyl; R^6 is hydrogen, hydroxy or (C_{1-4})alkyl; or where X^3
contains an $-NR^5R^6$ group, R^5 and R^6 together with the nitrogen atom to which they are
both attached, form hetero(C_{3-10})cycloalkyl, hetero(C_{5-10})aryl or hetero(C_{8-10})bicycloaryl;
 R^7 is hydrogen or (C_{1-4})alkyl and R^8 is hydroxy or R^7 and R^8 together form oxo; R^{16} is
hydrogen, $-X^4$, $-CF_3$, $-CF_2CF_2R^9$ or $-N(R^6)OR^6$; R^9 is hydrogen, halo, (C_{1-4})alkyl,

(C_{5-10}) aryl (C_{0-6}) alkyl or (C_{5-10}) heteroaryl (C_{0-6}) alkyl, with the proviso that when X^3 is cyano, then X^2 is hydrogen, fluoro, $-OH$, $-OR^4$ or $-NR^{17}R^{18}$ and X^7 is hydrogen or X^2 and X^7 both represent fluoro;

X^4 is a heteromonocyclic ring containing 4 to 7 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof, with the proviso that when X^4 is other than a heteromonocyclic ring containing 5 ring member atoms, wherein no more than two of the ring member atoms comprising the ring are heteroatoms, then X^2 is fluoro, $-OH$, $-OR^4$, $-NHR^{15}$ or $-NR^{17}R^{18}$ and X^7 is hydrogen or X^2 and X^7 both represent fluoro;

wherein within R^5 , X^3 or X^4 any alicyclic or aromatic ring system is unsubstituted or substituted further by 1 to 5 radicals independently selected from (C_{1-6}) alkyl, (C_{1-6}) alkylidene, cyano, halo, halo-substituted (C_{1-4}) alkyl, nitro, $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)OR^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$ and $-X^5S(O)_2R^{13}$ and/or 1 radical selected from $-R^{14}$, $-X^5OR^{14}$, $-X^5SR^{14}$, $-X^5S(O)R^{14}$, $-X^5S(O)_2R^{14}$, $-X^5C(O)R^{14}$, $-X^5C(O)OR^{14}$, $-X^5OC(O)R^{14}$, $-X^5NR^{14}R^{12}$, $-X^5NR^{12}C(O)R^{14}$, $-X^5NR^{12}C(O)OR^{14}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{14}R^{12}$, $-X^5NR^{12}S(O)_2R^{14}$, $-X^5NR^{12}C(O)NR^{14}R^{12}$ and $-X^5NR^{12}C(NR^{13})NR^{14}R^{12}$, wherein X^5 is a bond or (C_{1-6}) alkylene;

R^{12} at each occurrence independently is hydrogen, (C_{1-5}) alkyl ~~(C_{1-6}) alkyl~~ or halo-substituted (C_{1-6}) alkyl;

R^{13} is (C_{1-6}) alkyl or halo-substituted (C_{1-6}) alkyl; and

R^{14} is (C_{3-10}) cycloalkyl (C_{0-6}) alkyl, ~~hetero (C_{3-10}) cycloalkyl (C_{0-6}) alkyl~~, (C_{6-10}) aryl (C_{0-6}) alkyl, ~~hetero (C_{5-10}) aryl (C_{0-6}) alkyl~~, or (C_{9-10}) bicycloaryl (C_{0-6}) alkyl or ~~hetero (C_{8-10}) bicycloaryl (C_{0-6}) alkyl~~;

R^1 is hydrogen or (C_{1-6}) alkyl and R^2 is selected from a group consisting of hydrogen, cyano, $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-R^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)R^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$, $-X^5S(O)_2R^{13}$, $-R^{14}$, $-X^5OR^{14}$, $-X^5SR^{14}$, $-X^5S(O)R^{14}$, $-X^5S(O)_2R^{14}$, $-X^5C(O)R^{14}$, $-X^5C(O)OR^{14}$, $-X^5OC(O)R^{14}$, $-X^5NR^{14}R^{12}$, $-X^5NR^{12}C(O)R^{14}$, $-X^5NR^{12}C(O)OR^{14}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{14}R^{12}$, $-X^5NR^{12}S(O)_2R^{14}$, $-X^5NR^{12}C(O)NR^{14}R^{12}$ and $-X^5NR^{12}C(NR^{12})NR^{14}R^{12}$, wherein X^5 , R^{12} , R^{13} and R^{14} are as defined above; or R^1 and R^2 taken together with the carbon atom to which both R^1 and R^2 are attached form (C_{3-8}) cycloalkylene or (C_{3-8}) heterocycloalkylene; wherein within said R^2 any heteroaryl, aryl, cycloalkyl, heterocycloalkyl, cycloalkylene or heterocycloalkylene is unsubstituted or substituted with 1 to 3 radicals independently selected from (C_{1-6}) alkyl, (C_{1-6}) alkylidene, cyano, halo, halo-substituted (C_{1-4}) alkyl, nitro, $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)R^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$, $-X^5S(O)_2R^{13}$ and $-X^5C(O)R^{13}$, wherein X^5 , R^{12} and R^{13} are as defined above;

R^3 is (C_{1-6}) alkyl or $-C(R^6)(R^6)X^6$, wherein R^6 is hydrogen or (C_{1-6}) alkyl and X^6 is selected from $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)R^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5C(O)R^{13}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$, $-X^5S(O)_2R^{13}$, $-R^{14}$, $-X^5OR^{14}$, $-X^5SR^{14}$, $-X^5S(O)R^{14}$, $-X^5S(O)_2R^{14}$, $-X^5C(O)R^{14}$, $-X^5C(O)OR^{14}$, $-X^5OC(O)R^{14}$, $-X^5NR^{14}R^{12}$, $-X^5NR^{12}C(O)R^{14}$, $-X^5NR^{12}C(O)OR^{14}$, $-X^5C(O)NR^{14}R^{12}$, $-X^5S(O)_2NR^{14}R^{12}$, $-X^5NR^{12}S(O)_2R^{14}$, $-X^5NR^{12}C(O)NR^{14}R^{12}$ and $-X^5NR^{12}C(NR^{12})NR^{14}R^{12}$ wherein X^5 , R^{12} , R^{13} and R^{14} are as defined above;

R^4 is selected from $-X^8NR^{12}R^{12}$, $-X^8NR^{12}C(O)R^{12}$, $-X^8NR^{12}C(O)OR^{12}$,
 $-X^8NR^{12}C(O)NR^{12}R^{12}$, $-X^8NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^6OR^{12}$, $-X^8SR^{12}$, $-X^5C(O)OR^{12}$,
 $-X^5C(O)R^{12}$, $-X^6OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^8S(O)_2NR^{12}R^{12}$, $-X^8NR^{12}S(O)_2R^{12}$,
 $-X^8P(O)(OR^{12})OR^{12}$, $-X^8OP(O)(OR^{12})OR^{12}$, $-X^5C(O)R^{13}$, $-X^8NR^{12}C(O)R^{13}$, $-X^8S(O)R^{13}$,
 $-X^8S(O)_2R^{13}$, R^{14} , $-X^6OR^{14}$, $-X^8SR^{14}$, $-X^8S(O)R^{14}$, $-X^8S(O)_2R^{14}$, $-X^5C(O)R^{14}$,
 $-X^5C(O)OR^{14}$, $-X^8OC(O)R^{14}$, $-X^6NR^{14}R^{12}$, $-X^8NR^{12}C(O)R^{14}$, $-X^8NR^{12}C(O)OR^{14}$,
 $-X^5C(O)NR^{14}R^{12}$, $-X^8S(O)_2NR^{14}R^{12}$, $-X^6NR^{12}S(O)_2R^{14}$, $-X^8NR^{12}C(O)NR^{14}R^{12}$ and
 $-X^8NR^{12}C(NR^{12})NR^{14}R^{12}$ wherein X^8 is (C_{1-6}) alkylene and X^5 , R^{12} , R^{13} and R^{14} are as
defined above, with the proviso that when X^2 is cyano and X^3 is $-OR^4$, where R^4 is
defined as R^{14} , then R^{14} is (C_{2-10}) cycloalkyl, (C_{1-6}) alkyl, hetero (C_{2-10}) cycloalkyl, (C_{1-3}) alkyl,
 (C_{6-10}) aryl, (C_{1-6}) alkyl, hetero (C_{5-10}) aryl, (C_{1-6}) alkyl, (C_{9-10}) bicycloaryl, (C_{1-6}) alkyl or
hetero (C_{8-10}) bicycloaryl, (C_{1-6}) alkyl;

R^{15} is (C_{6-10}) aryl, hetero (C_{5-10}) aryl, (C_{9-10}) bicycloaryl or hetero (C_{8-10}) bicycloaryl;

R^{17} is (C_{1-6}) alkyl, (C_{2-10}) cycloalkyl, (C_{0-6}) alkyl, hetero (C_{2-10}) cycloalkyl, (C_{0-3}) alkyl,
 (C_{6-10}) aryl, (C_{0-6}) alkyl, hetero (C_{5-10}) aryl, (C_{0-6}) alkyl, (C_{9-10}) bicycloaryl, (C_{0-6}) alkyl or
hetero (C_{8-10}) bicycloaryl, (C_{0-6}) alkyl, with the proviso that when X^3 is cyano, then R^{17} is
 (C_{1-6}) alkyl, (C_{2-10}) cycloalkyl, (C_{1-6}) alkyl, hetero (C_{2-10}) cycloalkyl, (C_{1-6}) alkyl,
 (C_{6-10}) aryl, (C_{1-6}) alkyl, hetero (C_{5-10}) aryl, (C_{1-6}) alkyl, (C_{9-10}) bicycloaryl, (C_{1-6}) alkyl or
hetero (C_{8-10}) bicycloaryl, (C_{1-6}) alkyl;

R^{18} is hydrogen, (C_{1-6}) alkyl, (C_{2-10}) cycloalkyl, (C_{0-6}) alkyl,
hetero (C_{2-10}) cycloalkyl, (C_{0-6}) alkyl, (C_{6-10}) aryl, (C_{0-6}) alkyl, hetero (C_{5-10}) aryl, (C_{0-6}) alkyl,
 (C_{9-10}) bicycloaryl, (C_{0-6}) alkyl or hetero (C_{8-10}) bicycloaryl, (C_{0-6}) alkyl, with the proviso that
when X^3 is cyano, then R^{18} is (C_{1-6}) alkyl, (C_{2-10}) cycloalkyl, (C_{1-6}) alkyl,
hetero (C_{2-10}) cycloalkyl, (C_{1-6}) alkyl, (C_{6-10}) aryl, (C_{1-6}) alkyl, hetero (C_{5-10}) aryl, (C_{1-6}) alkyl,
 (C_{9-10}) bicycloaryl, (C_{1-6}) alkyl or hetero (C_{8-10}) bicycloaryl, (C_{1-6}) alkyl; and

wherein within R^3 , R^4 , R^{15} , R^{17} and R^{18} any aliphatic or aromatic ring system is
unsubstituted or substituted further by 1 to 5 radicals independently selected from

(C₁₋₆)alkyl, (C₁₋₆)alkylidene, cyano, halo, halo-substituted(C₁₋₄)alkyl, nitro, -X⁵NR¹²R¹², -X⁵NR¹²C(O)R¹², -X⁵NR¹²C(O)OR¹², -X⁵NR¹²C(O)NR¹²R¹², -X⁵NR¹²C(NR¹²)NR¹²R¹², -X⁵OR¹², -X⁵SR¹², -X⁵C(O)OR¹², -X⁵C(O)R¹², -X⁵OC(O)R¹², -X⁵C(O)NR¹²R¹², -X⁵S(O)₂NR¹²R¹², -X⁵NR¹²S(O)₂R¹², -X⁵P(O)(OR¹²)OR¹², -X⁵OP(O)(OR¹²)OR¹², -X⁵NR¹²C(O)R¹³, -X⁵S(O)R¹³, -X⁵C(O)R¹³ and -X⁵S(O)₂R¹³ and/or 1 radical selected from -R¹⁴, -X⁵OR¹⁴, -X⁵SR¹⁴, -X⁵S(O)R¹⁴, -X⁵S(O)₂R¹⁴, -X⁵C(O)R¹⁴, -X⁵C(O)OR¹⁴, -X⁵OC(O)R¹⁴, -X⁵NR¹⁴R¹², -X⁵NR¹²C(O)R¹⁴, -X⁵NR¹²C(O)OR¹⁴, -X⁵C(O)NR¹⁴R¹², -X⁵S(O)₂NR¹⁴R¹², -X⁵NR¹²S(O)₂R¹⁴, -X⁵NR¹²C(O)NR¹⁴R¹² and -X⁵NR¹²C(NR¹³)NR¹⁴R¹²; and within R³ and R⁴ any aliphatic moiety is unsubstituted or substituted further by 1 to 5 radicals independently selected from cyano, halo, nitro, -NR¹²R¹², -NR¹²C(O)R¹², -NR¹²C(O)OR¹², -NR¹²C(O)NR¹²R¹², -NR¹²C(NR¹²)NR¹²R¹², -OR¹², -SR¹², -C(O)OR¹², -C(O)R¹², -OC(O)R¹², -C(O)NR¹²R¹², -S(O)₂NR¹²R¹², -NR¹²S(O)₂R¹², -P(O)(OR¹²)OR¹², -OP(O)(OR¹²)OR¹², -NR¹²C(O)R¹³, -S(O)R¹³ and -S(O)₂R¹³; wherein X⁵, R¹², R¹³ and R¹⁴ are as described above, with the proviso that when X⁵ is cyano and X² is -OR⁴, where R⁴ is defined as -R¹⁴, or -NHR¹⁶, then any aromatic ring system present within R¹⁴ or R¹⁶ is not substituted further by halo, (C₃₋₁₀)cycloalkyl, hetero(C₃₋₁₀)cycloalkyl, (C₆₋₁₀)aryl, hetero(C₆₋₁₀)aryl, (C₉₋₁₀)bicycloaryl or hetero(C₈₋₁₀)bicycloaryl; with the proviso that only one bicyclic ring structure is present within R³, R⁴ or R¹⁶; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.

2-7. (Cancelled)

8. (Currently Amended) The compound of Claim 1 [[3]] in which:

X¹ is -NHC(R¹)(R²)X³ or -NHCH(R¹⁰)C(O)R²⁰, wherein R¹ is hydrogen or (C₁₋₆)alkyl and R² is hydrogen, (C₁₋₆)alkyl, -X⁵OR¹³, -X⁵S(O)R¹³, -X⁵OR¹⁴, (C₆₋₁₀)aryl(C₀₋₆)alkyl or

hetero(C₅₋₁₀)aryl(C₀₋₆)alkyl or R¹ and R² taken together with the carbon atom to which both R¹ and R² are attached form (C₃₋₆)cycloalkylene or (C₃₋₆)heterocycloalkylene, wherein within said R² any heteroaryl, aryl, cycloalkylene or heterocycloalkylene is unsubstituted or substituted with (C₁₋₆)alkyl or hydroxy, wherein X³ is cyano, C(O)R¹⁶, C(R⁶)(OR⁶)₂, CH=CHS(O)₂R⁵, CH₂C(O)R¹⁶, C(O)CF₂C(O)NR⁵, C(O)C(O)NR⁵R⁶, C(O)C(O)OR⁵, C(O)CH₂OR⁵, C(O)CH₂N(R⁶)SO₂R⁵ or C(O)C(O)R⁵ and R¹⁹ and R²⁰ together with the atoms to which R¹⁹ and R²⁰ are attached form (C₄₋₈)heterocycloalkylene, wherein no more than one of the ring member atoms comprising the ring is a heteroatom selected from NR²¹ or O, wherein the ring is unsubstituted or substituted with (C₁₋₆)alkyl or X⁵C(O)OR¹² and R²¹ is hydrogen, (C₁₋₆)alkyl, X⁵C(O)R¹², X⁵C(O)OR¹², R¹⁴, X⁵C(O)R¹⁴ or C(O)OR¹⁴;

X² is OH or OC(O)NR¹²R¹², wherein each R¹² independently represent hydrogen or (C₁₋₆)alkyl, wherein said alkyl is unsubstituted or substituted with hydroxy or methoxy, or X² is OC(O)NHR¹⁴, wherein R¹⁴ is (C₃₋₁₀)cycloalkyl(C₀₋₆)alkyl or hetero(C₃₋₁₀)cycloalkyl(C₁₋₃)alkyl, or X² is OC(O)R¹⁴, wherein R¹⁴ is NR²²R²³ and R²² and R²³ together with the nitrogen atom to which both R²² and R²³ attached form a hetero(C₄₋₆)cycloalkyl ring, which ring may be unsubstituted or substituted with hydroxy; and

R³ is -CH₂X⁶; wherein X⁶ is selected from X⁵SR¹², X⁵C(O)NR¹²R¹², X⁵S(O)₂R¹³, X⁵C(O)R¹³, X⁵OR¹², X⁵SR¹⁴, X⁵R¹⁴, X⁵S(O)₂R¹⁴, X⁵C(O)R¹⁴, X⁵C(O)NR¹⁴R¹²; and or the pharmaceutically acceptable salts and or solvates of such compounds and or the N-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and or mixtures of stereoisomers thereof.

9. (Currently Amended) The compound of Claim 8 in which:

X³ is cyano, C(O)X⁴, C(O)H, C(O)N(CH₃)OCH₃, CH(OCH₃)₂, C(O)CF₃, C(O)CF₂CF₃, CH₂C(O)R¹⁶, (E)-2-benzenesulfonyl-vinyl,

2-dimethylcarbamoyl-2,2-difluoro-acetyl, 2-oxo-2-pyrrolidin-1-yl-acetyl, 2-morpholin-4-yl-2-oxo-acetyl, 2-oxo-2-piperazin-1-yl-acetyl, 2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-acetyl, 2-(1,1-dioxo-1 λ^6 -thiomorpholin-4-yl)-2-oxo-acetyl, dimethylaminooxalyl-, tetrahydro-pyran-4-ylaminooxalyl-, 2-morpholin-4-yl-ethylaminooxalyl-, cyclopentyl-ethylaminooxalyl-, pyridin-3-ylaminooxalyl-, phenylaminooxalyl-, 1-benzoyl-piperidin-4-ylaminooxalyl-, 1-benzylcarbamoyl-methanoyl-, 1-benzyloxy(oxalyl)-, 2-benzyloxy-acetyl-, 2-benzenesulfonylamino-ethanoyl-, 2-oxo-2-phenyl-ethanoyl-, 3*H*-oxazole-2-carbonyl-, 5-trifluoromethyl-oxazole-2-carbonyl-, 3-trifluoromethyl-[1,2,4]oxadiazole-5-carbonyl-, 2,2,3,3,3-pentafluoro-propionyl-, hydroxyaminooxalyl-, oxalyl-, 2-(1,3-dihydro-isoindol-2-yl)-2-oxo-acetyl-, benzothiazol-2-ylaminooxalyl-, 2-oxo-ethyl-, 2-oxazol-2-yl-2-oxo-ethyl- or 2-benzooxazol-2-yl-2-oxo-ethyl-;

X² is selected from -OH, dimethylcarbamoyloxy, morpholin-4-ylcarbonyloxy-, piperidin-1-yl-carbonyloxy, pyrrolidin-1-yl-carbonyloxy, pyrimidin-2-ylamino-, tetrahydro-pyran-4-ylamino-, 1-methyl-piperidin-4-ylamino-, *N*-(2-methoxyethyl)-*N*-(tetrahydro-pyran-4-yl)amino-, isopropylamino- and cyclohexylamino-, 4-*tert*-butoxycarbonylpiperazin-1-ylcarbonyloxy-, *N*-benzyl-carbamoyloxy-, pyrrolidin-1-yl-carbonyloxy-, *N,N*-dimethyl-carbamoyloxy-, piperidin-1-yl-carbonyloxy-, 4-methanesulfonyl-piperazin-1-yl-carbonyloxy-, 4-ethoxycarbonylpiperazin-1-ylcarbonyloxy-, *N*-cyclohexyl-carbamoyloxy-, *N*-phenyl-carbamoyloxy-, *N*-(5,6,7,8-tetrahydro-naphthalen-1-yl)-carbamoyloxy-, *N*-butyl-*N*-methyl-carbamoyloxy-, *N*-pyridin-3-yl-carbamoyloxy-, *N*-isopropyl-carbamoyloxy-, *N*-pyridin-4-yl-carbamoyloxy-, *N*-cyanomethyl-*N*-methyl-carbamoyloxy-, *N,N*-bis-(2-methoxy-ethyl)-carbamoyloxy-, *N*-phenethyl-carbamoyloxy-, piperazine-carbonyloxy-, *N*-naphthalen-2-yl-carbamoyloxy-, 4-benzyl-piperazine-1-carbamoyloxy-, 4-(1-furan-2-yl-carbonyl)-piperazine-1-carbamoyloxy-, thiomorpholin-4-yl-carbonyloxy-, 1,1-dioxo-1 λ^6 -thiomorpholin-4-yl-carbonyloxy-, bis-(2-methoxy-ethyl)-carbamoyloxy-, morpholin-4-ylcarbonyloxy-, 2-methoxyethylcarbamoyloxy-, diethylcarbamoyloxy-, pyrrolidin-1-ylcarbonyloxy-, 2-hydroxyethylcarbamoyloxy-, tetrahydro-furan-2-ylmethylcarbamoyloxy-,

eyclopropylcarbamoyloxy, *tert*-butylcarbamoyloxy, 3-hydroxy-pyrrolidin-1-yl-carbonyloxy and carbamoyloxy; and

R³ is ~~thiophene-2-sulfonyl-methyl~~, 3-chloro-2-fluoro-phenyl-methane-sulfonyl-methyl, benzene-sulfonyl-methyl, phenyl-methane-sulfonyl-methyl, 2-(1,1-difluoro-methoxy)-phenyl-methane-sulfonyl-methyl, 2-benzene-sulfonyl-ethyl, 2-(pyridine-2-sulfonyl)-ethyl, 2-(pyridine-4-sulfonyl)-ethyl, 2-phenyl-methanesulfonyl-ethyl, oxy-pyridin-2-yl-methane-sulfonyl-methyl, prop-2-ene-1-sulfonyl-methyl, 4-methoxy-phenyl-methane-sulfonyl-methyl, *p*-tolyl-methane-sulfonyl-methyl, 4-chloro-phenyl-methane-sulfonyl-methyl, *o*-tolyl-methane-sulfonyl-methyl, 3,5-dimethyl-phenyl-methane-sulfonyl-methyl, 4-trifluoro-methyl-phenyl-methane-sulfonyl-methyl, 4-trifluoro-methoxy-phenyl-methane-sulfonyl-methyl, 2-bromo-phenyl-methane-sulfonyl-methyl, ~~pyridin-2-yl-methane-sulfonyl-methyl~~, ~~pyridin-3-yl-methane-sulfonyl-methyl~~, ~~pyridin-4-yl-methane-sulfonyl-methyl~~, naphthalen-2-yl-methane-sulfonyl-methyl, 3-methyl-phenyl-methane-sulfonyl-methyl, 3-trifluoro-methyl-phenyl-methane-sulfonyl-methyl, 3-trifluoro-methoxy-phenyl-methane-sulfonyl-methyl, 4-fluoro-2-trifluoromethoxy-phenyl-methane-sulfonylmethyl, 2-fluoro-6-trifluoromethyl-phenylmethanesulfonylmethyl, 3-chloro-phenylmethanesulfonylmethyl, 2-fluoro-phenylmethanesulfonylmethyl, 2-trifluoro-phenylmethanesulfonylmethyl, 2-cyano-phenylmethanesulfonylmethyl, 4-*tert*-butyl-phenylmethanesulfonylmethyl, 2-fluoro-3-methyl-phenyl-methane-sulfonyl-methyl, 3-fluoro-phenylmethanesulfonylmethyl, 4-fluoro-phenylmethane-sulfonylmethyl, 2-chloro-phenylmethanesulfonylmethyl, 2,5-difluoro-phenylmethane-sulfonylmethyl, 2,6-difluoro-phenylmethanesulfonylmethyl, 2,5-dichloro-phenyl-methane-sulfonylmethyl, 3,4-dichloro-phenylmethanesulfonylmethyl, 2-(1,1-difluoro-methoxy)-phenyl-methanesulfonylmethyl, 2-cyano-phenyl-methane-sulfonyl-methyl, 3-cyano-phenylmethanesulfonylmethyl, 2-trifluoro-methoxy-phenyl-methane-sulfonylmethyl, 2,3-difluoro-phenylmethanesulfonylmethyl, 2,5-difluoro-phenyl-methanesulfonylmethyl, biphenyl-2-ylmethanesulfonylmethyl, ~~eyclohexylmethyl~~,

3-fluoro-phenyl-methanesulfonylmethyl, 3,4-difluoro-phenyl-methanesulfonylmethyl, 2,4-difluoro-phenylmethanesulfonylmethyl, 2,4,6-trifluoro-phenylmethanesulfonylmethyl, 2,4,5-trifluoro-phenylmethanesulfonylmethyl, 2,3,4-trifluoro-phenylmethanesulfonylmethyl, 2,3,5-trifluoro-phenyl-methanesulfonylmethyl, 2,5,6-trifluoro-phenylmethanesulfonylmethyl, 2-chloro-5-trifluoro-methylphenylmethanesulfonylmethyl, ~~2-methyl-propane-1-sulfonyl~~, 2-fluoro-3-trifluoro-methylphenylmethanesulfonylmethyl, 2-fluoro-4-trifluoro-methylphenylmethanesulfonylmethyl, 2-fluoro-5-trifluoro-methyl-phenyl-methanesulfonyl-methyl, 4-fluoro-3-trifluoro-methylphenylmethanesulfonylmethyl, 2-methoxy-phenyl-methanesulfonylmethyl, 3,5-bis-trifluoromethyl-phenylmethanesulfonylmethyl, 4-difluoromethoxy-phenylmethanesulfonylmethyl, 2-difluoro-methoxy-phenyl-methanesulfonylmethyl, 3-difluoromethoxy-phenylmethanesulfonylmethyl, 2,6-dichloro-phenylmethanesulfonylmethyl, biphenyl-4-ylmethanesulfonylmethyl, ~~3,5-dimethyl isoxazol-4-ylmethanesulfonylmethyl~~, ~~5-chloro-thien-2-yl-methanesulfonylmethyl~~, 2-[4-(1,1-difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-[2-(1,1-difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-[3-(1,1-difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-(4-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(3-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(2-trifluoro-methoxy-benzene-sulfonyl)-ethyl, ~~(cyanomethyl-methyl-carbamoyl)-methyl~~, ~~biphenyl-3-ylmethyl~~, ~~2-oxo-2-pyrrolidin-1-yl-ethyl~~, 2-benzenesulfonyl-ethyl, ~~isobutylsulfanylmethyl~~, ~~2-phenylsulfanyl-ethyl~~, cyclohexylmethanesulfonylmethyl, 2-cyclohexyl-ethanesulfonyl, benzyl, ~~naphthalen-2-yl~~, benzylsulfanylmethyl, 2-trifluoromethyl-benzylsulfanylmethyl, phenylsulfanyl-ethyl, cyclopropyl-methanesulfonylmethyl, ~~5-bromo-thien-2-ylmethyl~~, ~~3-phenyl-propyl~~, 2,2-difluoro-3-phenyl-propyl, 3,4,5-trimethoxy-phenylmethanesulfonylmethyl, 2,2-difluoro-3-thien-2-yl-propyl, cyclohexylethyl, cyclohexylmethyl, *tert*-butylmethyl, 1-methylcyclohexylmethyl, 1-methylcyclopentylmethyl, 2,2-difluoro-3-phenylpropyl, 2,2-dimethyl-3-phenylpropyl, 1-benzylcyclopropylmethyl, $-X^5S(O)_2R^{13}$ and $-X^3S(O)_2R^{14}$, wherein R^{13} is alkyl and R^{14} is

phenyl which phenyl is unsubstituted or substituted; and the pharmaceutically acceptable salts and solvates of such compounds and the *N*-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.

10. (Currently Amended) A compound of Claim 9 in which:

X^3 is *1H*-benzimidazol-2-ylcarbonyl, pyrimidin-2-ylcarbonyl, benzooxazol-2-ylcarbonyl, benzothiazol-2-ylcarbonyl, pyridazin-3-ylcarbonyl, 3-phenyl-[1,2,4]oxadiazol-5-ylcarbonyl or 3-ethyl-[1,2,4]oxadiazol-5-ylcarbonyl, 2-oxo-2-pyrrolidin-1-yl-acetyl, 2-morpholin-4-yl-2-oxo-acetyl, 2-oxo-2-piperazin-1-yl-acetyl, 2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-acetyl, 2-(1,1-dioxo-1-thiomorpholin-4-yl)-2-oxo-acetyl, dimethylaminooxalyl, tetrahydro-pyran-4-ylaminooxalyl, 2-morpholin-4-yl-ethylaminooxalyl, cyclopentyl-ethyl-aminooxalyl, pyridin-3-ylaminooxalyl, phenylaminooxalyl or 1-benzoyl-piperidin-4-ylaminooxalyl;

X^2 is selected from -OH, dimethylcarbamoyloxy, morpholin-4-ylcarbonyloxy, piperidin-1-yl-carbonyloxy, pyrrolidin-1-yl-carbonyloxy, pyrimidin-2-ylamino, tetrahydro-pyran-4-ylamino, 1-methyl-piperidin-4-ylamino, *N*-(2-methoxyethyl)-*N*-(tetrahydro-pyran-4-yl)amino, isopropylamino and cyclohexylamino;

R^3 is cyclohexylethyl, cyclohexylmethyl, *tert*-butylmethyl, 1-methylcyclohexylmethyl, 1-methylcyclopentylmethyl, 2,2-difluoro-3-phenylpropyl, 2,2-dimethyl-3-phenylpropyl, 1-benzylecyclopropylmethyl, $-X^5S(O)_2R^{13}$ or $-X^5S(O)_2R^{14}$, wherein R^{13} is alkyl and R^{14} is phenyl which phenyl is unsubstituted or substituted; and the pharmaceutically acceptable salts and solvates of such compounds and the *N*-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.

11-13. (Cancelled).

14. (Currently Amended) A compound of Claim 1 selected from the group consisting of:

(*R*)-*N*-cyanomethyl-2-hydroxy-3-phenylmethanesulfonyl-propionamide;

(*R*)-*N*-(1-cyano-1-thiophen-2-yl-methyl)-2-hydroxy-3-phenylmethanesulfonyl-propionamide;

(*R*)-*N*-(1-cyano-1-thiophen-2-yl-methyl)-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;

(*R*)-*N*-cyanomethyl-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;

morpholine-4-carboxylic acid (*R*)-1-(cyanomethyl-carbamoyl)-2-phenylmethanesulfonyl-ethyl ester;

morpholine-4-carboxylic acid (*R*)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl ester;

(*R*)-(2-methoxy-ethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-phenylmethanesulfonyl-ethyl ester;

(*S*)-diethyl-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(*S*)-pyrrolidine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(*S*)-morpholine-4-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(*S*)-4-Ethyl-piperazine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(*S*)-2-hydroxymethyl-pyrrolidine-1-carboxylic acid (*S*)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(*S*)-(2,2,2-Trifluoro-ethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(*S*)-(2-hydroxyethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(Tetrahydrofuran-2-ylmethyl)-carbamic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(S)-Azetidine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(S)-cyclopropyl-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(S)-piperidine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(S)-(2-methoxy-ethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(R)-3-hydroxy-pyrrolidine-1-carboxylic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(S)-3-hydroxy-pyrrolidine-1-carboxylic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;

(S)-morpholine-4-carboxylic acid 1-(cyanomethyl-carbamoyl)-3-cyclohexyl-propyl ester;

morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester; and

morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl ester;

morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzothiazol-2-yl-methanoyl)-propylcarbamoyl]-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl ester;

pyrrolidine-1-carboxylic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;

dimethyl-carbamic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;

morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzylcarbamoyl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;

morpholine-4-carboxylic acid (S)-1-[(S)-1-(oxazolo[4,5-b]pyridine-2-carbonyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;

morpholine-4-carboxylic acid (S)-1-[(S)-1-(5-ethyl-[1,3,4]oxadiazole-2-carbonyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;

(S)-2-[(R)-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propanoylamino]-N-methoxy-N-methyl-butylamide;

(R)-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-N-[(S)-1-formyl-propyl]-2-hydroxy-propionamide;

(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-2-hydroxy-3-phenyl-methanesulfonyl-propionamide;

(S)-3-[3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-propanoylamino]-2-oxo-pentanoic acid-benzylamide;

N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-propionamide;

N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-3-phenyl-propyl]-3-*p*-tolylmethanesulfonyl-propionamide;

3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-(1-ethyl-2,3-dioxo-3-pyrrolidin-1-yl-propyl)-propionamide;

3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-(1-ethyl-3-morpholin-4-yl-2,3-dioxo-propyl)-propionamide;

3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-(1-ethyl-2,3-dioxo-3-piperazin-1-yl-propyl)-propionamide;

3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-[3-(1,1-dioxo-H6-thiomorpholin-4-yl)-1-ethyl-2,3-dioxo-propyl]-propionamide;

3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-[1-ethyl-3-(4-methyl-sulfonyl-piperazin-1-yl)-2,3-dioxo-propyl]-propionamide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-dimethylamide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-cyclopentyl-ethyl-amide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-phenylamide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-pyridin-3-ylamide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-(tetrahydro-pyran-4-yl)-amide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-(1-benzoyl-piperidin-4-yl)-amide;

3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-(2-morpholin-4-yl-ethyl)-amide;

(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-2-(2-nitro-phenylamino)-3-phenylmethanesulfonyl-propionamide;

N-[1-(benzooxazole-2-carbonyl)-propyl]-3-phenylmethanesulfonyl-2-(pyrimidin-2-ylamino)-propionamide.

(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-butyl]-2-(5-nitro-thiazol-2-ylamino)-3-phenylmethanesulfonyl-propionamide;

(2S)-(4,4-difluoro-2-hydroxy-5-phenyl-pentanoic acid (1(S)-cyano-3-phenyl-propyl)-amide;

N-(1(S)-cyano-3-phenyl-propyl)-2-(S)-(2-morpholin-4-yl-2-oxo-ethoxy)-4-phenyl-butyramide;

N-(1-(S)-cyano-3-phenyl-propyl)-2-(S)-fluoro-4-phenyl-butyramide;

N-(1-(S)-cyano-3-phenyl-propyl)-2,2-difluoro-4-phenyl-butyramide;

N-(1-(S)-cyano-3-phenyl-propyl)-2-(S)-hydroxy-4-phenyl-butyramide;

N-(1-(S)-cyano-3-phenyl-propyl)-2-(R)-hydroxy-4-phenyl-butyramide;
N-(1-(S)-cyano-3-phenyl-propyl)-2-(R)-methoxy-4-phenyl-butyramide;
2,2-difluoro-5-phenyl-pentanoic acid (1-cyano-cyclopropyl)-amide;
N-(1-(S)-cyano-3-phenyl-propyl)-4-phenyl-butyramide;
2,2-difluoro-5-phenyl-pentanoic acid ((S)-1-cyano-3-phenyl-propyl)-amide;
N-(4-cyano-1-ethyl-piperidin-4-yl)-3-cyclohexyl-propionamide;
N-(4-cyano-1-ethyl-piperidin-4-yl)-3-(2-difluoromethoxy-phenylmethanesulfonyl)-
propionamide;
(S)-tert-butyl-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;
(R)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-(2-difluoromethoxy-
phenylmethanesulfonyl)-ethyl ester;
(S)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;
(R)-morpholine-4-carboxylic acid 1-(1-cyano-cyclopropyl-carbamoyl)-2-
phenylmethanesulfonyl-ethyl ester;
(R)-morpholine-4-carboxylic acid 1-(4-cyano-tetrahydro-pyran-4-yl-carbamoyl)-2-
phenylmethanesulfonyl-ethyl ester;
3-cyclohexyl-2-hydroxy-N-[1-(oxazolo[4,5-b]pyridine-2-carbonyl)-propyl]-propionamide;
(R)-N-[1-(benzothiazole-2-carbonyl)-butyl]-2-isopropylamino-3-
phenylmethanesulfonyl-propionamide;
(R)-N-[1-(benzothiazole-2-carbonyl)-butyl]-3-phenylmethanesulfonyl-2-
(tetrahydro-pyran-4-ylamino)-propionamide;
(R)-N-[1-(benzothiazole-2-carbonyl)-butyl]-2-dibenzylamino-3-
phenylmethanesulfonyl-propionamide;
(R)-N-[1-(benzothiazole-2-carbonyl)-butyl]-2-dimethylamino-3-
phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-3-phenylmethanesulfonyl-2-
(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-(1-methyl-piperidin-4-ylamino)-3-phenylmethanesulfonyl-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-(bis-thiophen-2-ylmethyl-amino)-3-phenylmethanesulfonyl-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-dibenzylamino-3-phenylmethanesulfonyl-propionamide;

(S)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-(tetrahydro-pyran-4-ylamino)-3-thiophen-2-yl-propionamide;

(S)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-isopropylamino-3-thiophen-2-yl-propionamide;

(R)-N-[1-(benzothiazole-2-carbonyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-isopropylamino-3-phenylmethanesulfonyl-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-[(2-methoxy-ethyl)-(tetrahydro-pyran-4-yl)-amino]-3-phenylmethanesulfonyl-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-cyclohexylamino-3-phenylmethanesulfonyl-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-dimethylamino-3-phenylmethanesulfonyl-propionamide;

(1S)-N-[1-(benzoxazole-2-carbonyl)-butyl]-2-(S)-fluoro-4-phenyl-butyramide;
2,2-difluoro-5-phenyl-pentanoic acid [(S)-1-(benzoxazole-2-carbonyl)-butyl] amide;

morpholine-4-carboxylic acid (S)-1-[(S)-1-(benzoxazole-2-carbonyl)-propylearbamoyl]-2-cyclohexyl-ethyl ester;

morpholine-4-carboxylic acid (S)-2-cyclohexyl-1-[(S)-1-(oxazolo[4,5-b]pyridine-2-carbonyl)-propylearbamoyl]-ethyl ester;

morpholine 4-carboxylic acid (S)-2-cyclohexyl-1-[(S)-1-(5-ethyl-[1,3,4]oxadiazole-2-carbonyl)-propylcarbamoyl]-ethyl ester;

morpholine 4-carboxylic acid (S)-2-cyclohexyl-1-[(S)-1-(5-phenyl-[1,3,4]oxadiazole-2-carbonyl)-propylcarbamoyl]-ethyl ester;

morpholine 4-carboxylic acid (S)-1-[(S)-1-(benzoxazole-2-carbonyl)-propylcarbamoyl]-3-cyclohexyl-propyl ester;

4-[4,4-dimethyl-2-(morpholine-4-carboxyloxy)-pentanoylamino]-3-oxo-azepane-1-carboxylic acid-benzyl ester;

-(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-3-cyclopropylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;

-(R)-N-[1-(benzoxazole-2-carbonyl)-butyl]-2-cyclohexylamino-3-cyclopropylmethanesulfonyl-propionamide;

(R)-N-[1-(benzoxazole-2-carbonyl)-butyl]-2-cycloheptylamino-3-cyclopropylmethanesulfonyl-propionamide;

(R)-3-phenylmethanesulfonyl-N-[(S)-3-phenyl-1-(thiazole-2-carbonyl)-propyl]-2-(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-3-phenyl-propyl]-3-cyclopropylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-3-cyclopropylmethanesulfonyl-N-[1-(5-ethyl-1,2,4-oxadiazole-3-carbonyl)-propyl]-2-(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-3-phenylmethanesulfonyl-N-[1-(3-phenyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-2-(tetrahydro-pyran-4-ylamino)-propionamide;

(R)-N-[1-(3-cyclopropyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;

{(R)-1-[1-(benzothiazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(S)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-thiophen-2-yl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[1-(benzothiazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

(R)-1-[1-[hydroxy-(3-phenyl-1,2,4-oxadiazol-5-yl)-methyl]-propylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

((R)-2-cyclopropylmethanesulfonyl-1-[(S)-1-[(5-ethyl-1,2,4-oxadiazol-3-yl)-hydroxy-methyl]-propylearbamoyl]-ethyl)-carbamic acid-tert-butyl ester;

{(R)-1-[1-(benzoxazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-3-phenyl-propylearbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(hydroxy-thiazol-2-yl-methyl)-3-phenyl-propylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

(R)-1-[1-[hydroxy-(3-phenyl-1,2,4-oxadiazol-5-yl)-methyl]-propylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

((R)-2-cyclopropylmethanesulfonyl-1-[(S)-1-[(5-ethyl-1,2,4-oxadiazol-3-yl)-hydroxy-methyl]-propylearbamoyl]-ethyl)-carbamic acid-tert-butyl ester;

{(R)-1-[1-(benzoxazol-2-yl-hydroxy-methyl)-butylearbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-3-phenyl-propylearbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;

{(R)-1-[(S)-1-(hydroxy-thiazol-2-yl-methyl)-3-phenyl-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid-tert-butyl ester;
(R)-2-phenylmethanesulfonyl-1-[(S)-1-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-hydroxy-methyl]-propylcarbamoyl]-ethyl)-carbamic acid-tert-butyl ester;
(R)-N-[1-(Benzoxazol-2-carbonyl)-butyl]-2-[cyclopropylmethyl-(tetrahydro-pyran-4-ylmethyl)-amino]-3-phenylmethanesulfonyl-propionamide;
(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-2-dibenzylamino-3-phenylmethanesulfonyl-propionamide;
(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;
(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-2-isopropylamino-3-phenylmethanesulfonyl-propionamide;
(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-2-dimethylamino-3-phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-(1-methyl-piperidin-4-ylamino)-3-phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-(bis-thiophen-2-ylmethyl-amino)-3-phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-dibenzylamino-3-phenylmethanesulfonyl-propionamide;
(S)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-(tetrahydro-pyran-4-ylamino)-3-thiophen-2-yl-propionamide;
(S)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-isopropylamino-3-thiophen-2-yl-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-isopropylamino-3-phenylmethanesulfonyl-propionamide;

(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;
R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-[(2-methoxy-ethyl)-(tetrahydro-pyran-4-yl)-amino]-3-phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-cyclohexylamino-3-phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-dimethylamino-3-phenylmethanesulfonyl-propionamide;
N-cyanomethyl-3-cyclohexyl-propionamide;
N-cyanomethyl-3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionamide;
3-(3-cyclohexyl-propionylamino)-2-oxo-5-phenyl-pentanoic acid-thiazol-2-ylamide;
3-cyclohexyl-N-(1-formyl-3-phenyl-propyl)-propionamide;
3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-[(S)-1-(5-ethyl-[1,3,4]oxadiazole-2-carbonyl)-propyl]-propionamide;
N-[(S)-1-(benzooxazol-2-carbonyl)-propyl]-2-(2-cyano-phenylamino)-3-cyclohexyl-propionamide;
N-Cyanomethyl-3-cyclohexyl-2-(4-methoxy-phenoxy)-propionamide;
2-benzyloxy-N-cyanomethyl-3-cyclohexyl-propionamide;
(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-butyl]-2-benzyloxy-3-phenylmethanesulfonyl-propionamide;
(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-2-methoxymethoxy-3-phenylmethanesulfonyl-propionamide;
(S)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-butyl]-2-hydroxy-3-phenyl-propionamide;

(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-3-phenylmethanesulfonyl-2-triisopropylsilyloxy-propionamide;

(R)-N-[(S)-1-(1-benzothiazol-2-yl-methanoyl)-propyl]-2-hydroxy-3-phenylmethanesulfonyl-propionamide;

(R)-2-hydroxy-3-phenylmethanesulfonyl-N-[(S)-1-(1-pyridazin-3-yl-methanoyl)-butyl]-propionamide;

(S)-3-((R)-2-hydroxy-3-phenylmethanesulfonyl-propanoylamino)-2-oxo-pentanoic-acid-benzylamide;

(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;

(R)-N-[(S)-1-(1-benzothiazol-2-yl-methanoyl)-propyl]-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;

(2R,5S)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonylmethyl]-6-ethoxy-5-ethyl-morpholin-3-one; or their corresponding N oxides, and their prodrugs, and their protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N oxides and their prodrugs, and their protected derivatives, individual isomers and mixtures of isomers thereof, and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.

15-16. (Cancelled)

17. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

18. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 2 in combination with a pharmaceutically acceptable excipient.

19-20. (Cancelled)